Gossamer Bio, Inc. (GOSS)
GOSS moved a median of -0.70% 30 minutes after news, and -0.73% by the close. How GOSS actually reacts to news — the realized, point-in-time move the market made, measured across 693 labeled events over the last three years with zero look-ahead.
GOSS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.38% | 41% | 693 |
| 30-min | -0.70% | 37% | 693 |
| 60-min | -0.61% | 41% | 693 |
| to close | -0.73% | 46% | 691 |
| Middle 50% of GOSS reactions | -3.13% to +0.81% |
|---|---|
| Median reaction (30-min) | -0.70% |
| Measured reactions | 693 |
Half of all Gossamer Bio, Inc. news events land between -3.13% and +0.81% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How GOSS reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 17 | -1.83% | 12% | +4.27% |
| Coverage initiations | 10 | +0.88% | 60% | +8.51% |
| Rating reiterations | 58 | +0.24% | 53% | +0.70% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how GOSS ranks against every other measured name →
That’s how GOSS usually reacts — get an email when it moves on news →Email me when GOSS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to GOSS's baseline. Nothing else.
Recent GOSS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Gossamer Bio, Inc. For: Sep 25 | SEC filing · Form 8-K | SEC EDGAR | -1.58% | -0.86% | |
| Form 8-K Gossamer Bio, Inc. For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | +2.23% | +1.58% | |
| Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension | Press release | Business Wire | +2.23% | +1.58% | |
| Form 8-K Gossamer Bio, Inc. For: Sep 16 | SEC filing · Form 8-K | SEC EDGAR | -4.16% | +1.36% | |
| Form DEF 14A Gossamer Bio, Inc. For: Oct 27 | SEC filing · Form DEF | SEC EDGAR | -4.16% | +1.36% | |
| Gossamer Bio Appoints Greg Ciongoli to Board of Directors | Press release | Business Wire | -4.16% | +1.36% | |
| Form 8-K Gossamer Bio, Inc. For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | -10.66% | -14.02% | |
| Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split | Press release | Business Wire | -10.66% | -14.02% | |
| Form 8-K Gossamer Bio, Inc. For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | +2.40% | +6.47% | |
| Gossamer Bio Announces 1-for-80 Reverse Stock Split | Press release | Business Wire | +2.40% | +6.47% | |
| Form D Gossamer Bio, Inc. | SEC filing · Form D | SEC EDGAR | -0.82% | +4.90% | |
| Gossamer Bio to Present at Cantor Global Healthcare Conference | Press release | Business Wire | -1.05% | +2.22% | |
| Form 8-K Gossamer Bio, Inc. For: Sep 03 | SEC filing · Form 8-K | SEC EDGAR | -1.05% | +2.22% | |
| Form PRE 14A Gossamer Bio, Inc. For: Sep 03 | SEC filing · Form PRE | SEC EDGAR | -1.05% | +2.22% | |
| Form 8-K Gossamer Bio, Inc. For: Aug 24 | SEC filing · Form 8-K | SEC EDGAR | -4.60% | -3.41% | |
| Form 8-K Gossamer Bio, Inc. For: Aug 20 | SEC filing · Form 8-K | SEC EDGAR | -5.66% | -8.73% | |
| Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval | Press release | Business Wire | -5.66% | -8.73% | |
| Form 10-Q Gossamer Bio, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.50% | -9.29% | |
| Form 8-K Gossamer Bio, Inc. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | -3.50% | -9.29% | |
| Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update | Press release | Business Wire | -3.50% | -9.29% | |
| Form 8-K Gossamer Bio, Inc. For: Jul 23 | SEC filing · Form 8-K | SEC EDGAR | -11.56% | -23.50% | |
| Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update | Press release | Business Wire | +0.77% | +17.29% | |
| Form 8-K Gossamer Bio, Inc. For: Jul 14 | SEC filing · Form 8-K | SEC EDGAR | +0.53% | +21.76% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Gossamer Bio, Inc. (GOSS) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.01% | +1.92% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Gossamer Bio, Inc. (GOSS) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.98% | +12.53% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Gossamer Bio, Inc. (GOSS) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -0.35% | +1.64% | |
| Form 8-K Gossamer Bio, Inc. For: Jul 01 | SEC filing · Form 8-K | SEC EDGAR | +1.32% | +0.42% | |
| Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants | Press release | Business Wire | +1.32% | +0.42% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Gossamer Bio, Inc. (GOSS) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.51% | -1.50% | |
| Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +1.79% | -4.78% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Gossamer Bio, Inc. (GOSS) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -4.71% | -6.76% | |
| Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.27% | +2.47% | |
| Form 8-K Gossamer Bio, Inc. For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +1.91% | +14.01% | |
| Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes | Press release | Business Wire | +1.91% | +14.01% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Gossamer Bio, Inc. (GOSS) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.35% | -0.89% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Gossamer Bio, Inc. (GOSS) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +1.94% | -1.76% | |
| Form DEF 14A Gossamer Bio, Inc. For: Jul 14 | SEC filing · Form DEF | SEC EDGAR | -2.22% | -0.89% | |
| Form 8-K Gossamer Bio, Inc. For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | -1.50% | -2.72% | |
| Form 8-K Gossamer Bio, Inc. For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | -1.50% | -2.72% | |
| Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes | Press release | Business Wire | -4.40% | -5.85% | |
| Form 8-K Gossamer Bio, Inc. For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | -1.91% | -0.94% | |
| Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes | Press release | Business Wire | -1.91% | -0.94% | |
| Gossamer Bio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GOSS | Press release | PR Newswire | -5.83% | -14.50% | |
| Gossamer Bio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GOSS | Press release | PR Newswire | -6.64% | -4.22% | |
| Form 8-K Gossamer Bio, Inc. For: May 18 | SEC filing · Form 8-K | SEC EDGAR | -12.97% | -35.77% | |
| Form DEFA14A Gossamer Bio, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -12.97% | -35.77% | |
| Form PRE 14A Gossamer Bio, Inc. For: May 18 | SEC filing · Form PRE | SEC EDGAR | -12.97% | -35.77% | |
| Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update | Press release | Business Wire | -12.97% | -35.77% | |
| Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support | Press release | Business Wire | -12.97% | -35.77% | |
| Form 10-Q Gossamer Bio, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -12.97% | -35.77% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the GOSS section they belong to.
Where else GOSS is measured.
GOSS earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Gossamer Bio, Inc.'s median reaction calculated?
Every labeled GOSS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 693 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 37% of GOSS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does GOSS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.